Pod Insights a16z Podcast Biotech CEO on where we are in the fight to cure cancer About this episode Jonathan Lim is the CEO of Erasca, but his career path took him on a fascinating journey from practicing as a surgeon to leading life science companies. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making.
Reflecting on a personal trip to the Galapagos Islands, Lim also drew parallels between Darwinian evolution and business. In today’s challenging biotech environment, entrepreneurs need to adapt or die, consistently evolving by reprioritizing, raising funds smartly, and staying agile to survive and thrive.
Resources:
Find Jorge on X: https://x.com/JorgeCondeBio
Learn more about a16z Bio+Health: https://a16z.com/bio-health/
Learn more about Raising Health: https://a16z.com/podcasts/raising-health/
Stay Updated:
Find a16z Bio+Health on LinkedIn: https://www.linkedin.com/showcase/a16z-bio-health/
Find a16z Bio+Health on X: https://x.com/a16zBioHealth
Subscribe on your favorite podcast app: https://a16z.com/podcasts/raising-health/
"Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures."
Transcript 0:14 Speaker 1 I am thrilled today to be hosting Jonathan Lim, the CEO of Erasca. Jonathan, thank you for being here today. Thanks,
0:22 Speaker 0 Jorge. It's awesome to be here.
0:23 Speaker 1 Why don't we start at the sort of at the top here, which is on you and your background? So you are the CEO of Erasca. You didn't start out on the business side. By background, you're a physician, and if memory serves, you were a surgeon. So walk me through the the sort of the trip from the operating room to the boardroom.
0:42 Speaker 0 Yeah, I grew up in San Diego just loving the movies and thinking maybe I'll be a filmmaker one day, but I also love science and wanted to be a doctor and really use science to help people. So I was pre-med at Stanford, went to back to Montreal where I was born and then uh went to McGill and then went straight into general surgery at New York Hospital. And I just loved it. So I was a really happy surgeon. Uh but I did a two-year uh break in Boston and I worked at Dana Farber Cancer Institute. So I did some cancer epidemiology research. Then I also did an MPH in healthcare management at Harvard School of Public Health. So that was my period of exploration. And during that time, I really decided, wow, entrepreneurship looks really cool.
1:29 Speaker 0 So I went to McKinsey for a couple of years. Oh man. And then uh down the dark path. Uh entered the dark side, and then I uh uh joined Halozyme when there were a four-person startup in 2003.
1:42 Speaker 1 A couple of interesting jumps in what you just described, being a practicing surgeon to a uh McKinsey, it seems like a leap, but in some ways those are pretty safe bets, right? From there, though, McKinsey to a four-person startup. Talk to me about that leap. Because that seems like uh the riskiest of the leaps from what you described.
1:59 Speaker 0 I'm a big believer in that that things happen for reason, uh, you know, based on my own uh Christian faith and other things. But my my dad introduced me to one of his patients who had a uh a venture capital startup. And uh her name's Audrey Viterbi. I um met her and she saw my background in surgery and McKinsey, and she thought, hey, you could be a CEO in biotech. And I thought she was joking, but then I got a call just a couple months later saying, hey, do you want to move to San Diego? I said, why? And she said, uh, we have this biotech startup that we'd like you to run. And so I was called in as the CEO. I got called in as a CEO. So I was 31 at the time. I knew nothing, I mean, I knew a little bit about biotech, because at McKinsey, I I served a broad range of clients across healthcare.
2:50 Speaker 0 Uh, but I mean, this was totally a leap of faith. And uh I was employee number five. Um, I didn't know what questions to ask. I didn't know what I didn't know. So we had three months of cash on hand, a company that had zero uh VC dollars invested. And uh we said, well, how do we go public? And so the idea of a reverse merger of Halozyme, the private company merging with a public shell company. So we were on the over-the-counter bulletin boards, and we uh traded for for a few months. Uh, let's see, we up listed to the American stock exchange about a year later, and then to the Nasdaq two and a half years later, and then the rest is history. So, yeah, really humble origins. Wow. Yeah.
3:34 Speaker 1 And what what was the stage of the company when you did this? We were preclinical. So preclinical company in 2003 without the. This was
3:41 Speaker 0 on enhanced technology. I mean, the technology itself, we knew it would work, but it's just we needed people to believe in it. And so uh we were able to then um really de-risk the uh technology and and uh we signed a deal with with Roche. So they took a leap of faith where we got that deal done in 30 days at the end of 2006. Wow. And then we became uh the fourth performing stock uh on the in the Wall Street Journal that year, and it was just amazing. Like all of a sudden we were on people's radars and we struck deals with with Roger and Baxter and a whole number of other companies for enhanced technology, which now uh halozyme is guiding to about a billion dollar in revenue uh in the next few years. Just based on the
4:24 Speaker 1 markable story. And then from Halozyme, what was your next uh leap?
4:29 Speaker 0 Then I uh started my own uh fund. It was a family office fund called City Hill Ventures, and this was the idea of found fund and lead different uh life science companies. So sort of took a broad view of of the healthcare industry, did some medical device, did some healthcare technology, did a lot of biotech, realized biotech really was my sweet spot. And so uh I started a number of companies, including Eclipse Therapeutics, which was a spin-out from Biogen IDEC, uh, started Ignita later uh that same year, uh joined them full-time in 2012 when Eclipse was acquired by Bionomics. So it was good early proof of concept. Wrote an article on it called Smallball Investing. Uh and then I ran Ignita for many years. I then started Bonte in 2015, which was a sort of a spin-out of technology from Allergan.
5:18 Speaker 0 And then both Ignita and Bonte were acquired in 2018 in the same year. So that that was a big year for for City Hill. So let's let's talk briefly about the Erasca story. We're obviously
5:30 Speaker 1 fortunate to have been
5:31 Speaker 0 uh another.
5:32 Speaker 1 Yeah, thank you for being there in the early days. Early stage investor in the company. It's been remarkable to see that the company's journey. So
5:37 Speaker 0 Erasca, the company's tagline is
5:39 Speaker 1 erase cancer, which is really where the name Erasca comes from.
5:42 Speaker 0 Right.
5:43 Speaker 1 Let's talk generally about cancer. And I want to go back and talk more about the biotechnology industry and your your journey as an entrepreneur. But if we just focus and uh zoom out for a second on the cancer landscape. Where do you think we are in that journey?
5:56 Speaker 0 So Erasca's mission, it's actually a portmanteau for with a double meaning. So one is erase cancer, the other is to eradicate RAS-driven cancer. So that's sort of embedded in in the uh the acronym, so to speak. But I would say we're making progress. We definitely are not where we need to be, but it's we're still early innings, and I think what's really encouraging is where we are today is significantly better than where we were five years. And so with every five-year increment, we just keep making progress. So it's just amazing to see the progress of of immunotherapy and and just how many um therapies we have at our disposal for different uh solid tumor types and liquid tumor types for that matter, uh, as you think about the uh monoclonal antibody approaches, the um even uh T cell therapies, CAR T, uh, other aspects.
6:46 Speaker 0 There's a lot to be excited and grateful for. But I think um what's most exciting is uh especially with the checkpoint inhibitors where you see the the long tail. So you see about 20% of patients that have long-term uh remission that that actually turns into into cures. And I think the the goal of the cancer fighting community has been how do we increase that long tail? So rather than 20% or one in five patients, how how can we get two in five or three in five? And so we're exploring a number of combinations. Um but then with targeted therapies, there's some really exciting breakthroughs, whether it's the some of the ADCs like uh in Hair 2, where you see just remarkable long-term survival outcomes, uh, OS and PFS with uh in breast cancer, and and now they're in uh five different indications, including tissue agnostic.
7:37 Speaker 0 And I think we're scratching the surface of the
7:40 Speaker 1 combinations
7:41 Speaker 0 uh that that we can explore.
7:42 Speaker 1 I put this out as a sort of a straw man argument. One would think that if cancer is primarily a disease of DNA, as we've gotten better at being able to sequence um uh tumors to sequence cancer to analyze it. Um how much has that illuminated our ability to figure out how to target cancer, how to find its Achilles heel. In other words, if we can understand cancer drivers, and if most cancer drivers are genetic in nature, can we work backwards by analyzing the genetics of all cancer and then come up with strategies for targeting tumors in a way that will actually help us uh beat cancers.
8:24 Speaker 0 Just a few years ago, I learned about EC DNA. So extra chromosomal DNA are these circles that basically tumors use to harbor uh massive uh oncogene amplification. And so uh most of the industry didn't even know that this circular chromosomal DNA was a mechanism for driving cancer as well as metastases and recurrence until Paul Michelle and others identified this and developed diagnostics to to look for it. And so that's some of the work that we're doing at Boundless Bio, which I co-founded with uh the folks over at Arch and uh and with Paul Michelle, and we're really excited about about that approach of of looking at the genetic vulnerabilities of these EC DNAs, and then using that to combine with some of the more traditional approaches as well.
9:18 Speaker 1 Yeah, and I think that's what's interesting and probably also frustrating about our field, which is the biology as proves to be the case again and again is is always more complex than we originally think.
9:29 Speaker 0 Right.
9:29 Speaker 1 Right. So we think, okay, we can and we can you know sequence tumors, we'll figure out where the mutations are, we'll figure out how to target them. But then we learn about things like EC uh DNA that just obviously complicates the picture. Right. Um on the one hand, in terms of figuring out what to go after. And on the other, one of the things that I think is reason to be optimistic, but there's still a long way to go, as you say, we're still scratching the surface, is we get increasingly better and um more sophisticated in the types of tools or the modalities that we develop to hit cancer with. The weapon. Weapons we have against cancer, that that armamentarium, that um that uh weapons um uh chest is expanding, right? Continues to expand. And so I think there's there's reason to give hope. If we were to flash forward five years from now, what would be your prediction on what what will have proven to be the next sort of set of great leaps forward?
10:20 Speaker 0 Well, I think we're learning more and more. I think we're taking new chemical modalities and approaches to shutting down different oncogene drivers or quote unquote undruggable targets. So I think the modalities are really exciting, even in our own experience at Arasca. Uh, you know, revolution medicine uh here in town is uh a pioneer in the approach of taking uh molecular glue or cyclophylin A binder to drug RAS, which RAS in the active GTP state has historically been really difficult to uh to shut down, but we were really just uh so encouraged by their uh data. This was about a little more than a year ago uh regarding how they could take uh RMC 6236 and and shut down RAS in the active state and show responses in G12D and other types of tumors.
11:10 Speaker 0 And so we actually have our own uh cyclophylin A molecular glue called ERAS 15 that we just in-licensed, and we're really excited about that with even higher potency than RMC6236. But it's approaches like that that I think are really moving the needle, uh, whether alone or in combination with with other approaches, and it's what we need is to keep advancing the standard of care. Until RevMed showed that um that you could target RAS wild type, I actually was very skeptical that we'd be able to do that. But then when I saw the data, I was just amazed that this was safe and reasonably well tolerated. So it's really exciting to see the amount of progress that's happening with new modalities.
11:57 Speaker 0 And I think the
11:58 Speaker 1 the kinds of things you describe, like these sort of leaps forward give us lots of reasons to be optimistic. Right. That the next five years and beyond are are gonna continue to evolve in a way that will help us make great improvements in the in this field and in other disease areas as well. Shifting gears a bit, uh, what'd you do this summer?
12:16 Speaker 0 Well, one of the highlights is my family went on a trip to the Galapagos Islands. So this was uh uh basically a Stanford travel study program with Bill Durham, who is a faculty member. He taught in the human biology department at Stanford for for decades, and uh this was on our bucket list to to uh go on this trip, and it was just a once-in-a-lifetime opportunity.
12:39 Speaker 1 And Galapagos, of course, uh are the islands where Charles Darwin sails down there and and has the sort of Eureka realization around around natural selection
12:50 Speaker 0 and his whole theory is is born there. And believe it or not, I mean, he was in his 20s. I think he was 26 or something when he discovered this. And uh he was only there for for less than a month.
13:01 Speaker 1 So Charles Darwin goes down to Galapagos, spends some time there and comes up with the theory of evolution uh with the concept of survival of the fittest. You go down there this summer, you spend some time in Galapagos. What theories did you come up with?
13:17 Speaker 0 There's this bird called the frigate. And so most birds that that dive for fish, they have oil glands that basically you know cover their their feathers and allow them to not sink. Now the frigate bird has vestigial oil glands, so they can't do this. If they if they fish on their own and dive bomb, they're dead. And so they'll sink, they'll sink. Yeah. And so they've basically evolved to uh be bigger than all the other birds. So when the blue-footed boobies and the pelicans and the other birds dive bomb and get the fish, the frigates come in and they just take the fish away from them. And so they're called kleptoparasites, but there's
13:59 Speaker 1 this whole ecosystem of these bully birds. And do they fight them in the air or do they fight them on the
14:04 Speaker 0 fight them in the air? So they basically just intercept the and and take, you know, they they basically wrest the the fish away from from the other birds. And so that's just evolution uh at work. And then um, you know, in terms of the the flora, there are these trees that are called uh scales, they're named after one of the scientists. And if you look closely, the trees are they're beautiful. They almost look like Dr. Seuss types of trees because they're just so exotic. Uh they're actually daisies if you do the genetic analysis. And so, how do daisies become trees? Well, it's again very Darwinian in terms of um, you know, herbaceous plants sort of fighting as bushes for sunlight and scarce resources, but these daisies just keep growing and they grow as far as they can and become trees just so that they can outcompete the other uh plants.
14:59 Speaker 0 And so when you draw the parallels with our industry, I mean, clearly uh, you know, some of the lessons are you adapt or die. So if you don't learn to adapt in our industry, you're not around very very long. And last few years, I think have been sobering for all of us, uh, Erasca included, it's just been really tough and very Darwinian in terms of competition for uh, you know, attention from investors, attention from partners, attention from employees, uh, you know, in terms of the war for talent. So it's just been really tough. And so you have to adapt or die. And so we've done a lot of uh pivoting in terms of uh prioritizations and reprioritizations and trying to get access to capital and and trying to have uh programs that that people really care about and they can really move the needle for patients, and then the rest takes care of itself.
15:54 Speaker 0 And I think everyone's trying to do that. But then it's really the realization that um we all need to embrace change and and embrace it, not just to survive, but to thrive. So in addition to defense, there's also offense. So at Erasca, we're focused on the RAS map kinase pathway. Uh our lead program in the clinic is a compound called Napal Rafinib, which is a pan RAF inhibitor. And we're super excited about that for NRAS mutant melanoma. But NRAS mutant melanoma, there's about uh 50,000 patients total in in the US. It's definitely an unmet need, but it's not a massive one. And so we were looking at different programs that could really move the needle for hundreds of thousands of of people uh in the US and globally.
16:40 Speaker 0 And so we were able to in-license successfully two uh RAS targeting programs. One is uh a pan-RAS molecular glue, as I mentioned earlier, and then the other is a uh KRAS selective pan-KRAS uh small molecule inhibitor. And so we're really excited about those programs and the ability to combine with standard of care uh in uh pancreatic cancer, in lung cancer, colon cancer, other solid tumor types, and then with each other. And then if you combine it with the molecular glue for any uh acquired resistance mutations, then that could really be
17:16 Speaker 1 the interesting combo. If I'm a founder, if I'm an entrepreneur to an entrepreneur today, and I'm sort of navigating through what is a very difficult environment, the very inhospitable environment.
17:26 Speaker 0 Yeah.
17:26 Speaker 1 What are some of the adaptations that I should have front of mind?
17:29 Speaker 0 Yeah, no, I mean, I think the I would say that uh don't be afraid to pivot. And if you're gonna pivot, pivot fast. So the faster you make the decision, the better. All the companies I've been at. There's always been one or multiple pivots. And so at Erasca, uh, you know, we we actually have had sort of three epics at the company. So in the early days, we were focused on discovery for new uh RAS targeting agents, and then we sort of brought in a number of assets and we went public, as you'll recall around the ERC targeting program. And then we uh brought in uh NAPO RAFINIB from Novartis, and that's a really exciting program. But I think high probability of success, but in terms of moving the needle on a massive unmet need, probably not as much.
18:20 Speaker 0 And so then we brought in uh the latest, which are these two RAS targeting agents, and now the the enthusiasm uh amongst uh the buy-side and sell side uh is is really very high. So I think we're we're in the the sweet spot right now. And so it's really sort of embracing uh the uncertainty, but but applying creativity, resilience, and and uh decisive uh
18:44 Speaker 1 action to uh to navigate
18:45 Speaker 0 that.
18:46 Speaker 1 Yeah, and that's that I think that's a key point, right? Because pivoting is daunting. So now if we look at the landscape broadly, um it's a challenging environment for all the reasons we've said. Is there a silver lining? Is there anything out there on the landscape that you'd say, look, this is actually uh, you know, these are calm Cs to maybe you know, head towards uh if you're an early stage company. The answer may be no.
19:09 Speaker 0 Yeah. No, I mean, I think the pendulum always swings back and forth between platforms and products and back again. I think we're back in the product uh cycle where I think really focusing on what is that product or therapeutic that's really gonna move the needle for patients. And so there's a number of AI companies that are really building that drug development expertise to take a product or products further into the pipeline to be able to generate the clinical data that investors and partners want to see. So I think that's really the playbook at this point in this environment. People want to see what impact can you have on patients, whether it's uh discharging safety or showing uh efficacy proof of concept.
19:54 Speaker 0 I think it's really important to show what your therapeutic can do. Um, and then it's really just Marshalling the resources uh to focus on that on what's really going to move the needle. And by the way, when the pendulum does go back, raise money, but really treat it as if you know you're in a in a bear market as opposed to a bull market. So I think you know, one of the things that we did right at Eraska was when we went public in 2021, day one after the IPO, we said now that we have all this money, what are we gonna do with it? We're not gonna spend it. We're actually gonna save it. And so we we knew that the pendulum was gonna swing back, it was gonna be tougher uh days ahead.
20:38 Speaker 1 So
20:38 Speaker 0 we've
20:38 Speaker 1 talked about pivots, we've talked about creativity, we've talked about pendulum squin uh swinging. Uh one of the most remarkable pendulum swings pivots uh that encompasses creativity, I think would apply to you. You said at the very beginning uh you loved Hollywood. Um you started your your fund, City Hill Ventures, and you said it primarily invested in biotechnology companies. That is evolving.
21:07 Speaker 0 Right.
21:08 Speaker 1 So now you're an invest you're investing in things that are very much not biotechnology companies.
21:13 Speaker 0 Very Darwinian, isn't it? It very
21:15 Speaker 1 much is. So talk to me a little bit about that.
21:18 Speaker 0 Yeah. So uh yeah, I was born in Montreal, grew up in Southern California, but in 2018 when Ignito was was bought by Roche, it allowed me to take three months off. So I was off the grid. I put my iPhone in the drawer. My wife got me a flip phone with a different number. Uh you had a burner? I had a burner phone. Yeah. Believe it or not. I still have it, but I don't use it anymore. I just prayed, I reflected, I spent a lot of quality time with family, friends, traveled, uh did a lot of creative pursuits. So I came back in October, we hit the ground running with Erasca, and then later that year, I started uh a company called City Hill Arts, which is an offshoot of City Hill. And so the idea is to revitalize people, planet, and perspective.
22:04 Speaker 0 It was just this idea that can we shape people's hearts and minds in a powerful way with inspiring stories, hopeful stories, stories of love, kindness, stories that that bring people together and unite us and show us what unites us as opposed to divides us. And so out of that came uh this slate of movies that uh embody those kinds of stories. And so we are genre agnostic, but really the unifying theme is what unites us and and stories with heart. So you make movies now. I make movies now, yeah. So uh I
22:37 Speaker 1 think I can't tell you how cool that is, by the way.
22:39 Speaker 0 Thank you. No, I I feel so blessed to be doing what I love in terms of the twin passions of science and biotech and and arts in the movies. So I'm gonna attempt to use Hollywood industry terms, but
22:51 Speaker 1 what's on the slate of movie? What's on the slate? Is that even how you pronounce it? Yeah, yeah, that's it. Okay, so what's on the slate in terms of movies that are coming down the
22:59 Speaker 0 pipe? So uh the first big movie for us uh is showing in theaters now. It's called My Penguin Friend. So it's a story inspired by a true story between a Brazilian fisherman that came across this Argentinian penguin all covered in oil. The fisherman nursed him back to health, and then every year the penguin swam thousands of miles from Patagonia to this fisherman's remote village in Illa Grande, Brazil. So that happened every year for eight years. That's the true story. It blew up on social media in 2016, and then one of our uh producers tracked down uh the real fisherman, and he basically got his life rights, and we cast 10 real penguins in the role of uh Dindim. So about 80% of the movie is shot with real penguins.
23:46 Speaker 0 You can't put penguins in peril though. So uh 15% is with CGI and then five percent is
23:52 Speaker 1 with uh puppets or animatronics. Oh wow. Yeah. Well, first of all, you talk about stories that unite. You're telling the story of a Brazilian and an Argentinian getting along. Hey, so that's amazing in and of itself. That's a miracle,
24:02 Speaker 0 right? Um But that's the first, and then we have another movie, uh small movie called The Secret Art of Uh Human Flight. So it's about a widower who is grieving and uh he meets this guru who uh teaches him how to fly. Oh wow. Um is that also a true story? No. It's a grounded sci-fi, but uh it's gonna be a day and dates release uh actually this Friday, so uh people could see it in the theater as well as on streaming at the same time. Oh
24:31 Speaker 1 my goodness.
24:32 Speaker 0 Yeah, you guys are busy. Yeah, and then uh, you know, we've got some other uh movies that we're working on.
24:37 Speaker 1 Is there a comparison between the biotechnology industry and movie making? Because at the surface, you would think these feel pretty similar. You you're making an investment up front in the hope that you have a hit.
24:51 Speaker 0 Right.
24:51 Speaker 1 Right. Which is a hit is used both in biotech and movie making.
24:56 Speaker 0 There's actually an uncanny uh parallel between those two industries. So let's say a given project in the movie business. Uh let's take a really successful film, you know, uh the King's Speech won the Oscar. How how many years do you think that took to uh to make? I'm gonna guess a long time. I'm gonna say 10 years. Yeah, 13 years. My
25:19 Speaker 1 goodness.
25:19 Speaker 0 Yeah. So they call it in in Hollywood, they call it development hell, just because
25:23 Speaker 1 it
25:24 Speaker 0 it takes so long to get these movies made. So in our industry, you know, it's about eight to ten years for a typical drug to make it from the early beginnings to uh to launch. And in Hollywood, it's it's no different. I mean, there's a lot of nonlinear paths that that these movie projects uh take, and and there's a lot of stakeholders. Um and then the probability of success of any given project. So when you look at a drug, the POS really uh increases by stage. It's kind of the same in Hollywood, except that the uh outcome in terms of box office revenue and performance is really just imprecise. So there's no way to know whether a given project, I mean, I th I love penguins. I you probably love I don't know if anyone that doesn't love penguins, but I still have no idea how well my penguin friend's gonna do.
26:16 Speaker 0 And so you have to take a portfolio approach in uh you know the the film investment uh uh arena as you do in
26:24 Speaker 1 in biotech. So we were we depend on hits, we each have our own version of development hell, right? Right, in our case it's discovery and development hell. Is Dim still with us? Dindim is not with
26:34 Speaker 0 us, but the 10 rescue penguins are and in fact two of them fell in love on set. And so uh yeah, they were unusable because they would just stand back to back and stare off hopelessly in the distance. That's better. So we actually had eight penguins to work with.
26:51 Speaker 1 Well, Jonathan, I want to thank you so much for spending time with us today and really want to thank you more importantly for all that you do, not only for the magic of making movies, but all you've done for the magic of making medicines.
27:02 Speaker 0 Oh, thank you very much, Mark.
Previous How Andreessen Horowitz Disrupted VC & What’s Coming Next Next How to Enable a Manufacturing Renaissance Page updated August 25, 2026 · transcript and summary are machine-generated